ライフサイエンスコーパス: occult

1 total of 1929 eyes from 1730 subjects (1196 occult, 289 minimally classic, and 444 predominantly cla

2 >/= 0.2 logMAR in 4 (24 %) classic, 9 (47 %) occult, 6 (33 %) pigment epithelial detachment, 6 (55 %)

3 right ventricle (RV) was utilized to detect occult abnormalities in regional and global contractilit

4 is adaptable and scalable, able to quantify occult abnormalities, derive mechanistic insights, and d

5 There were no occult adrenocortical carcinomas.

6 Baseline CNV type other than occult and absence of retinal fluid and leakage at week

7 associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort.

8 ions were obscure gastrointestinal bleeding (occult/anemia or overt/active, OGIB) of 46% (246/536) an

9 dministered to these 60 patients to identify occult antigen exposure known to cause hypersensitivity

10 ional cancer detected at MR imaging that was occult at mammography.

11 diagnoses were screen-detected and six were occult at RRSO).

12 If these events are due to occult atheroma, the risk-factor profile and coronary pr

13 f these cases were attributed to exposure of occult avian antigens from commonly used feather bedding

14 , sometimes associated with radiographically occult avulsion fractures.

15 or S. pyogenes, explaining the phenomenon of occult bacteraemia.

16 Between 2001 and 2010, 759 true occult bacteremia cases were identified, including 65 pa

17 Occult bacterial infections represent a worldwide health

18 the clinical setting to identify previously occult biomarkers of drug sensitivity that can aid in th

19 e collected and assessed for consistency and occult bleeding.

20 patients who received the stool testing for occult blood (FOBT).

21 Participants who tested positive for faecal occult blood and who were eligible for and considered fi

22 tric ulcers, and a higher incidence of fecal occult blood loss.

23 e = 3,520; IRR = 0.87 (0.80-0.96) and Faecal Occult Blood Number eligible = 6,566; 0.86 (0.78-0.94).

24 r undergoing an immunological test for fecal occult blood or colonoscopy.

25 etter screening compliance compared to fecal occult blood or endoscopic screening.

26 ing test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low lev

27 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) scr

28 The Fecal Occult Blood Test (FOBT) is one of the diagnostic modali

29 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than th

30 165.19), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

31 reening, 2) FIT: annual immunochemical fecal occult blood test age 40-75 years, 3) gFOBT: annual guai

32 5 years, 3) gFOBT: annual guaiac-based fecal occult blood test age 40-75 years, and 4) COL: 10-yearly

33 erred for colonoscopy with a positive faecal occult blood test as part of the UK national bowel cance

34 anol, RNAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test t

35 The stool occult blood test continues to be utilized for reasons o

36 tal tests was defined by a record of a fecal occult blood test in the past 2 years, flexible sigmoido

37 agnostic indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57),

38 assing the first screening round of a faecal occult blood test screening programme in a single geogra

39 lonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 pers

40 colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55

41 ography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the mu

42 lonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonosc

43 f once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

44 f biennial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-sp

45 Screening Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

46 d clinical trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

47 s likely than nonphysicians to undergo fecal occult blood testing and were more likely to undergo col

48 sting or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10

49 55 years in addition to the biennial faecal occult blood testing programme offered to all individual

50 Screening with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT)

51 ears to be lower than that with guaiac fecal occult blood testing.

52 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

53 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colore

54 , with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonosco

55 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality pers

56 In randomized trials, fecal occult-blood testing reduces mortality from colorectal c

57 r to annual or biennial screening with fecal occult-blood testing.

58 One patient with occult brain metastasis had grade 4 intracranial hemorrh

59 an detect subcentimeter and mammographically occult breast cancer, with a sensitivity and specificity

60 BSGI examinations detected mammographically occult breast cancer.

61 st cancer and the number of mammographically occult breast cancers detected per 1,000 women screened.

62 A substantial number of mammographically occult breast lesions, either benign or malignant, could

63 ulated as the percentage of mammographically occult BSGI-detected breast cancer and the number of mam

64 chnic venous thrombosis (SVT) is a marker of occult cancer and a prognostic factor for cancer surviva

65 Its significance as a first symptom of occult cancer and as a prognostic factor for cancer surv

66 Pericarditis may be a marker of occult cancer and augurs increased mortality after a can

67 domization, 33 (3.9%) had a new diagnosis of occult cancer between randomization and the 1-year follo

68 Risk factors predictive of occult cancer detection in patients with a first unprovo

69 moking status may be important predictors of occult cancer detection in patients with first unprovoke

70 ssess the effect of specific risk factors on occult cancer detection within 1 year of a diagnosis of

71 CI, 1.24-6.33; P= .014) were associated with occult cancer detection.

72 differing exposure windows and estimates of occult cancer duration and is similar to those from CRC

73 versity in practices regarding screening for occult cancer in a person who has an unprovoked venous t

74 To estimate the prevalence of occult cancer in patients with unprovoked VTE, including

75 Occult cancer is detected in 1 in 20 patients within a y

76 ess the efficacy of a screening strategy for occult cancer that included comprehensive computed tomog

77 lonoscopy receipt prior to presumed onset of occult cancer was associated with an approximately 60% r

78 Clinically occult cancer was detected among 2.6% of high-risk women

79 The prevalence of occult cancer was low among patients with a first unprov

80 ical practice and can sometimes be a sign of occult cancer.

81 .6 years, and found that SVT was a marker of occult cancer.

82 creatic ductal adenocarcinoma, a notoriously occult cancer.

83 ts were randomly assigned to undergo limited occult-cancer screening (basic blood testing, chest radi

84 t, cervical, and prostate cancer) or limited occult-cancer screening in combination with CT.

85 In the primary outcome analysis, 4 occult cancers (29%) were missed by the limited screenin

86 65 days after prior screen, with modeling of occult cancers detected at RRSO.

87 gical age, and anatomic origin of clinically occult cancers detected at surgery.

88 screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87

89 Of the six occult cancers, five (83.3%) were stage I to II (CI, 35.

90 luence the progression of early subclinical (occult) cancers.

91 embers should undergo clinical screening for occult cardiac disease, but the diagnostic yield from sc

92 he consequence (rather than the cause) of an occult cardiomyopathy, which persists despite a signific

93 We hypothesized that CMR would identify occult cardiotoxicity characterized by structural and fu

94 In an asymptomatic population, there is occult cardiovascular disease which can be detected by c

95 is safe and efficacious for the diagnosis of occult CBD stones in patients with intermediate risk for

96 Occult cerebral microhemorrhage is common in patients wi

97 estimation of tumor thickness and predicting occult cervical nodal metastasis.

98 Stage 3 resembles occult choroidal neovascularization, occurs primarily in

99 The effect of occult cirrhosis (OcC), defined as preclinical compensat

100 66), 28.6% (76/266), and 9.8% (26/266) among occult, classic, retinal angiomatous proliferation, and

101 e the ribonuclease H (RH) domain contains an occult cleavage site located near its center, cleavage m

102 ed gain of 15 letters or more than eyes with occult CNV (mean BCVA, 57.9 letters at baseline; P < 0.0

103 dal neovascularization (CNV) than those with occult CNV (P < 0.001).

104 Eyes with occult CNV at baseline showed higher incidence rates of

105 area (DA); lesions were subfoveal in 40.5%, occult CNV composition was present in 54.8%, and associa

106 n of PCV and differentiation between PCV and occult CNV in this selected clinic population.

107 to 100% of cases identified by FFA only were occult CNV lesions.

108 chments (PEDs) attributable to either PCV or occult CNV were retrospectively reviewed by a grader mas

109 rization (CNV) leakage area, smaller area of occult CNV, and presence of subretinal fluid (SRF).

110 ization (CNV) (aHR, 3.1; CI, 2.4-3.9) versus occult CNV, blocked fluorescence (aHR, 1.4; CI, 1.1-1.8)

111 thalmologists to distinguish between PCV and occult CNV, decreasing the need for ICGA and the risks r

112 o 10.90) compared with minimally classic and occult CNV, whereas the hazard ratio of fibrosis develop

113 n ICGA-confirmed diagnosis of PCV and 14 had occult CNV.

114 VA (mean [standard deviation]) was higher in occult CNVs (56.9 [17.4] letters) than in minimally (52.

115 Eyes with occult CNVs had overall a better VA than other CNVs.

116 At 5 years eyes with occult CNVs still had better VA than other CNVs.

117 Patients who fulfilled criteria for suspect "occult constipation" were then given a bowel cleaning re

118 ive magnetic resonance imaging (MRI) detects occult contralateral breast cancers (CBCs) in women with

119 Nevertheless, an occult contribution of PV-expressing interneurons to the

120 markers in predicting the presence of early occult disease and/or the screening and monitoring of in

121 extend treatment margins and treat presumed occult disease in 50% (n = 6).

122 tic modality enabling us to correctly detect occult disease in 74% of patients and to differentiate l

123 llege of Surgeons Oncology Group to evaluate occult disease in SLNs and bone marrow of early-stage br

124 ollected 2 to 5 years before diagnosis, when occult disease is probably present.

125 chool children, to identify risk factors for occult disease, and to assess the value of laboratory te

126 ught to be at risk for potentially harboring occult disease.

127 y recurrent micrometastases and for treating occult disease.

128 f target nodal groups most likely to harbour occult disease.

129 We argue that the occult effects of latent T.gondii infection likely outwe

130 ta in New York, we identified 843 women with occult endometrial carcinoma and 334 women with occult u

131 Among women with occult endometrial carcinoma, there was no significant a

132 be indistinguishable; the need to eliminate occult environmental factors known to cause pulmonary fi

133 elanoma on the head and neck, where clinical occult extension is common, were studied at an academic

134 y defined clinical margins and unpredictable occult extension.

135 esents a genome-wide copy number analysis of occult fallopian tube carcinomas identified through risk

136 which were associated with radiographically occult fibular avulsion fractures.

137 The frequency of occult fracture was higher in patients aged at least 80

138 ligament and disk injuries and contusion or occult fracture) for traumatic injuries.

139 The pooled rate of occult fracture, diagnostic performance of CT and bone s

140 of CT and bone scanning in the detection of occult fractures by using MRI as the reference standard.

141 c conditions of the wrist and hand including occult fractures, osteonecrosis, ligamentous and tendon

142 examinations to assess for radiographically occult fractures.

143 d 25.0% for patients with overt GI bleeding, occult GI bleeding, abdominal pain, chronic diarrhea, an

144 estinal (GI) bleeding, chronic diarrhea, and occult GI bleeding, accounting for 57.9%, 12.4%, and 9.7

145 trasonography and CT cannot reliably exclude occult groin abnormalities.

146 Occult HBV infection (OBI) is defined by the persistence

147 ed pregnant women with isolated anti-HBc and occult HBV infection have very low HBV DNA levels and ar

148 None of the women with isolated anti-HBc and occult HBV infection transmitted HBV to their infants.

149 Occult HBV infection was identified in 24% (95% CI, 18%-

150 men with isolated anti-HBc were assessed for occult HBV infection, defined as HBV DNA levels >15 IU/m

151 actors associated with isolated anti-HBc and occult HBV infection.

152 virus (HBV)infection but might also signify occult HBV infection.

153 In order to determine the prevalence of occult HBV reactivation in a large cohort of patients du

154 suppressive therapies, in order to detect an occult HBV reactivation.

155 Of these 14 patients, 9 were assessed for occult HCV infection by reverse transcription quantitati

156 These findings indicate the presence of occult HCV infection in some patients with abnormal leve

157 CV infection after liver transplantation had occult HCV infections.

158 t cerebral microbleeds (CMBs) as a marker of occult hemorrhage.

159 describe the establishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a succ

160 Occult hepatitis B virus (HBV) infection (OBI) is define

161 hether universal infant immunization affects occult hepatitis B virus (HBV) infection (OBI), serum sa

162 y to hepatitis B core antigen (anti-HBc) and occult hepatitis B virus (HBV) infection are not well kn

163 agnosis of hernia, MRI correctly detected an occult hernia in 10 of 11 cases (91%).

164 Early diagnosis and treatment of occult hernias are essential in relieving symptoms and i

165 Occult hernias are symptomatic but not palpable on physi

166 ormance in the detection of radiographically occult hip fracture (P = .67), with a sensitivity of 79%

167 o estimate the frequency of radiographically occult hip fracture in elderly patients, to define the h

168 initial radiography have a high frequency of occult hip fractures.

169 upport a model in which early development of occult hippocampal hyperexcitability may contribute to t

170 ET/CT may be clinically useful for detecting occult infection foci in end-stage renal disease patient

171 Occult infection with hepatitis C virus (HCV) is defined

172 ed that 55% of these patients (n = 5) had an occult infection, with the detection of negative strand

173 It is unclear if women with occult infections are at risk of transmitting HBV to the

174 Such occult infections are common during pregnancy but their

175 e values of US, CT, and MRI for detection of occult inguinal hernia.

176 A new regimen for screening of occult injuries to make allowance for this is proposed.

177 serous carcinoma appears to develop from an occult intraepithelial carcinoma in the fimbria of the f

178 The study evaluated the possibilities of occult invasion detected by immunohistochemistry, sectio

179 Few reports demonstrate occult invasion with immunohistochemistry staining, whic

180 nd Measures: Assessment of the occurrence of occult invasion, diagnosis of invasion by immunohistoche

181 Objective: To investigate the occurrence of occult invasive disease within in situ melanoma by using

182 intraepithelial neoplasia after exclusion of occult invasive disease.

183 Results: Occult invasive melanoma was detected in 11 of 33 consec

184 ned on 8 March 2015 ut as the limb of Europa occulted Io.

185 n psoriatic arthritis or unmasked previously occult joint disease.

186 lt uterine sarcoma, especially in those with occult leiomyosarcoma.

187 than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negati

188 c lesions were associated with worse VA than occult lesions (66 vs. 69 letters; P=0.0003).

189 Occult lesions became inactive more slowly than classic

190 ver, FFA may still be of value in those with occult lesions that appear quiescent on SD OCT, as this

191 cipants with classic, minimally classic, and occult lesions were randomized in a 2:1 ratio to EMBT or

192 cipants with classic, minimally classic, and occult lesions were randomized to receive (a) EMBT and 2

193 classic lesions may be more responsive than occult lesions, although generally both subgroups are in

194 stically significant (favoring controls) for occult lesions, but not for predominantly classic and mi

195 e visual acuity, most probably in cases with occult lesions.

196 c and minimally classic lesions, but not for occult lesions.

197 ubjects and four additional otherwise missed occult lesions.

198 s, optimize the day of surgery, and identify occult lesions.

199 ncluding the detection and quantification of occult lobular enlargement in the liver secondary to hil

200 ated a nomogram predicting the likelihood of occult lymph node metastases in surgically resectable es

201 tients with achromatopsia (3.3 mum/year) and occult macular dystrophy (1.2 mum/year).

202 ients with achromatopsia (16.2 mum/year) and occult macular dystrophy (15.4 mum/year).

203 Occult macular dystrophy was diagnosed based on genetic

204 ients with Stargardt disease, achromatopsia, occult macular dystrophy, and cone dystrophies (P < .003

205 extramacular commotio retinae may represent occult macular injury or previously undiagnosed visual i

206 aware that they can be the first sign of an occult malignancy and that early recognition is vital fo

207 in patients randomized in the Screening for Occult Malignancy in Patients with Idiopathic Venous Thr

208 f tumour signals, high-resolution imaging of occult malignancy is challenging.

209 reliminary study, a small number of cases of occult malignancy were subsequently diagnosed among preg

210 e should prompt a systemic evaluation for an occult malignancy, which may be critical for patient sur

211 anchnic vein thrombosis (SVT) as a marker of occult malignant disease.

212 use multiparameter flow cytometry to detect occult marrow disease (OMD) in patients with solitary pl

213 laboratory features suggest the presence of 'occult' mastocytosis or another haematologic neoplasm, a

214 n on noninvasive prenatal testing (NIPT) and occult maternal malignancies may explain results that ar

215 e patient underwent surgical excision of the occult melanoma without evidence of other sites of metas

216 eg, lack of residual membrane or presence of occult membrane), thus affecting additional surgical man

217 rders, such as Alzheimer's disease, in which occult mesial temporal lobe seizures are suspected to pl

218 owed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is

219 urative surgery by identifying patients with occult metastases.

220 In this respect, early detection of occult metastasis invisible to current imaging methods w

221 his finding resulted in identification of an occult metastatic melanoma involving the axillary lymph

222 spectively, with the last nucleotide used as occult microhomology.

223 omology in the majority of FLT3-ITDs through occult microhomology: specifically, by priming through u

224 Occult microinvasion was demonstrated in up to one-third

225 are variable, potentially due to undetected occult micrometastases (OM).

226 tal question arises as to whether clinically occult micrometastases survive in a state of balanced pr

227 increase pathological downstaging and act on occult micrometastatic disease, leading ultimately to a

228 CT images reveal otherwise occult muscle depletion.

229 y (n=27), myocarditis or sarcoidosis (n=22), occult myocardial infarction (n=13), and hypertrophic ca

230 ic lung resection performed in patients with occult N2 disease was 10.8% (18 of 166) (8.1% in the EBU

231 he rate of nontherapeutic lung resection for occult N2 disease, with comparison between the EBUS grou

232 rate of nontherapeutic operations because of occult N2 nodal disease.

233 unique histological features, the frequently occult nature of the underlying infection and the older

234 an reported in the literature because of its occult nature.

235 were associated with detection of clinically occult neoplasms at RRSO.

236 The primary occult NET was localized by (18)F-FDOPA PET/CT in 12 pat

237 uable diagnostic information by unmasking an occult neuroendocrine differentiation and identifying a

238 ata raise the possibility that persistent or occult neurologic and lymphoid disease may occur followi

239 t consistent on a cytomorphologic basis with occult nevi.

240 ificantly aids in the detection of otherwise occult nodal and bone metastases.

241 tion was used to estimate the probability of occult nodal disease as a function of total number of LN

242 des the first empirically based estimates of occult nodal disease risk in patients after surgery for

243 To rule out occult nodal disease with 90% confidence, six, nine, and

244 aging and outcomes through identification of occult nodal disease.

245 It is uncertain if occult nodal metastasis impacts survival.

246 Detection of OC and EC and even clinically occult OC was achieved, making it a potential tool of si

247 This also included one patient with occult OC.

248 Thirty-eight tumors were occult on mammograms.

249 tecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relatio

250 ential to localize PCa recurrence after HIFU occult on mpMRI.

251 aging tool for the detection of primary NETs occult on SRS, especially tumors with a well-differentia

252 ssic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01).

253 nflammation could represent individuals with occult opportunistic infections in need of additional sc

254 The presence of occult or early transformation is the main driver of POD

255 Treatment-naive eyes diagnosed with occult or minimally or predominantly classic CNV that co

256 ng DNA methylation profiles to determine the occult original cancer in cases of cancer of unknown pri

257 immune antibodies in 25 cases of acute zonal occult outer retinopathy (AZOOR) identified using the cl

258 Acute zonal occult outer retinopathy (AZOOR) remains a challenging d

259 Therefore, acute zonal occult outer retinopathy (AZOOR) was diagnosed.

260 ical entity that best represents acute zonal occult outer retinopathy (AZOOR).

261 or a distinct entity within the acute zonal occult outer retinopathy complex.

262 Acute zonal occult outer retinopathy should be considered in patient

263 classic (p = 0.105), 0.000 (-1.15, 0.20) in occult (p = 0.005), -0.200 (-1.20, 0.60) in cases with s

264 implicated in cryptogenic stroke, including occult paroxysmal atrial fibrillation, patent foramen ov

265 ciations found in a patient with acute zonal occult photoreceptor loss.

266 bitor-induced activation of wild-type Raf in occult precursor skin lesions.

267 , although generally rare, may also indicate occult prostate cancer that may need to be further scrut

268 g right heart catheterization would identify occult pulmonary venous hypertension (OPVH).

269 We aimed to investigate occult, putative causes in the environments of patients

270 Contamination by occult rectal bleeding was excluded by guaiac paper test

271 Contamination by occult rectal bleeding was ruled out by guaiac paper tes

272 Failure to control occult retinal vasculitis adequately may be a contributi

273 %) were found to show additional evidence of occult retinal vasculitis on FA.

274 ed posterior involvement for the presence of occult retinal vasculitis.

275 or who have complex cytogenetics should have occult RT excluded before initiating venetoclax therapy.

276 entional measures of function, suggestive of occult RV myocardial disease.

277 tinitis and optic neuritis in a patient with occult SCLC.

278 t case is an infiltrative breast cancer with occult sonography findings in a patient with a history o

279 igment epithelial detachment associated with occult subfoveal choroidal neovascularization with intra

280 The frequency of radiographically occult surgical hip fracture was 39% (1110 of 2835 patie

281 or lymphocytes is associated with clinically occult transition to donor-derived immunity.

282 Ocular Neovascularization; Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in th

283 roenvironment (niche) may affect the fate of occult tumor cells, including their biological and genet

284 of several techniques designed to locate an occult tumor, including cross-sectional anatomic imaging

285 use paraneoplastic disorders often herald an occult tumor.

286 With the high potential for occult tumors in common conditions such as fibroids, val

287 latives older than age 50 were found to have occult tumors; the tumors were cleared surgically from 8

288 the (64)Cu-labelled polymers detected small occult tumours (10-20 mm(3)) in the brain, head, neck an

289 nique opportunity to study the morphology of occult type 1 neovascular membranes in AMD and allows pr

290 Baseline occult-type choroidal neovascularization (CNV) (P = .015

291 n, estimated glomerular filtration rate, and occult UOC.

292 ether with additional signs of ATI indicates occult UOC.

293 adversely affect prognosis of patients with occult uterine cancer, empirical evidence has been limit

294 with increased mortality risk in women with occult uterine cancer.

295 ult endometrial carcinoma and 334 women with occult uterine sarcoma who underwent a hysterectomy or m

296 ted with higher mortality risk in women with occult uterine sarcoma, especially in those with occult

297 Among women with occult uterine sarcoma, LSH/LM was associated with a hig

298 VP40 and GP epitopes is observed suggesting occult viral persistence.

299 Occult wild-type transthyretin cardiac amyloid had a pre

300 orphological features, particularly TE, with occult (=without relevant hydronephrosis in US) UOC and